What Equine Vets Are Saying About Arthramid: Insights From the Melbourne and Sydney Clinical Symposia

Key takeaway: At invitation-only Arthramid clinical symposia in Melbourne and Sydney, the discussion among experienced equine veterinarians had largely moved past whether the treatment works and toward how to use it well. Five themes stood out: synovitis as a driver of joint disease, case selection, rehabilitation, telling a flare apart from sepsis, and where Arthramid fits within a broader treatment plan. 

In May, IMS Vet brought together some of Australia’s most experienced equine veterinarians for two clinical symposia, one in Melbourne and one in Sydney. These were invitation-only sessions with high-usage clinicians, so the themes below reflect advanced, real-world experience rather than the whole profession. They offer a useful read on where equine joint medicine is heading.

What the clinical discussion covered:

• Positive results across a range of joints, with Arthramid increasingly used early to address synovitis
• Typical duration reported by clinicians of 6 to 8 months in racehorses and 1 to 2 years in sport horses
• A low adverse event rate, with transient, self-limiting reactions reported in only a few cases
• Distinguishing a normal flare from sepsis as the key clinical skill
• Growing use after arthroscopy, often around four weeks post-surgery, for joint protection
• Arthramid used as part of a broader joint management plan, matched to the right case at the right time

Each of these is unpacked below.

The conversation has moved from “does it work” to “how do I use it well”

Among this group of experienced users, very little time was spent debating whether Arthramid works. The published evidence base is already established, so the discussion centered on application: which cases respond best, when to introduce treatment, how to rehabilitate, and how it fits alongside other therapies.
In practice, clinicians described the typical duration of effect varying with workload: around 6 to 8 months in racehorses and 1 to 2 years in sport horses. That sits comfortably alongside the sustained effect seen in published follow-up, and it gives a realistic time frame for the conversations clinicians have with owners and trainers.

This is a trajectory among experienced clinicians, not a verdict from the whole profession. For newer users, the evidence questions are still part of the journey.

How is synovitis reshaping treatment decisions?

Clinicians increasingly frame joint disease around synovial dysfunction rather than cartilage damage alone. The recurring point was that pain and progression are often driven by an unhealthy synovial environment, which changes both how cases are assessed and what a treatment is expected to do. Several described positive results across a range of joints, and a growing tendency to treat earlier, while synovitis is still the dominant feature, rather than waiting for structural change to advance.

This is where Arthramid acts. Once injected, the hydrogel integrates into the synovial membrane over 10 to 14 days (Lowe et al. 2024). It restores synovial elasticity and load transfer and supports better-quality joint fluid downstream.

The clinical takeaway from the room was practical, not molecular. The value of a synovium-focused approach is that it targets a root driver of joint disease rather than only masking the pain signal.

Which horses are the best candidates for Arthramid?

The strongest candidates are horses with an accurate, localised diagnosis. Case selection came up repeatedly as the single biggest determinant of a good outcome.

Candidates discussed as responding well:

•  Early to moderate osteoarthritis
• Chronic synovitis and persistent joint effusion
• Joints that have a positive reaction to flexion
• Joints that block close to 100% sound on intra-articular analgesia
• Post-arthroscopy cases, where joint protection is the goal
• Horses where repeated corticosteroid use is undesirable or contraindicated

Results were described as less predictable where pain is driven by significant periarticular change (e.g. subchondral bone) rather than the synovial environment, or where the source of lameness has not been confirmed to the joint. The question behind most of the case discussion was simple: is this a synovitis-driven joint, and is it the right joint?

Pro tip: At the 6-week reassessment, check the accuracy of the diagnosis before concluding a case has not responded. A flat response is often a case-selection or diagnostic issue rather than a product issue.

What does rehabilitation after Arthramid involve, and why do owners and trainers matter?

Rehabilitation centres on protecting the integration window, and clinicians repeatedly identified trainer behaviour as a factor that can make or break the result. Early return to work and unrealistic timelines were named as common reasons a sound treatment underdelivers.

Clinicians also noted that dose selection influences outcomes, with a consistent view that higher doses often produce more reliable responses. As a result, there was support for treating toward the upper end of the dosing range in appropriate cases, rather than defaulting to minimal dosing.

The standard approach:

• Rest for 48 hours after injection.
• Reintroduce light, low-impact work and build gradually over roughly two weeks.
• Avoid early return to full work during the integration period.
• Reassess at 4 to 6 weeks and consider a top-up if the response is partial.
• Where practical, treat during reduced workload or earlier in the training program than for a fast-acting option.

Expectation-setting was seen as part of the treatment, not an afterthought. Arthramid works gradually over the first four to six weeks, so aligning owners and trainers around the recovery period is as important as the injection itself.

How do you tell a treatment flare apart from sepsis?

A post-injection flare is a typically self-limiting, non-septic inflammatory reaction, whereas sepsis is an infection that needs different and urgent treatment. This was one of the most practical discussions, because the two can look similar in the early days and the clinical decision carries real consequences.

The shared message was confidence in diagnosis and avoiding unnecessary intervention. Transient, self-limiting reactions are reported in fewer than 1 in 2,500 injections, but when sepsis cannot be confidently excluded it must be treated as the working diagnosis. The differentiation rests on clinical assessment, laboratory analysis of synovial fluid and a clear, calm protocol that helps avoid both over-treatment and missed infection.

How does Arthramid fit alongside other joint therapies and surgery?

Arthramid was positioned within a broader joint management framework—not as a blanket substitute for other therapies. Clinicians emphasised its role as a selective, case-dependent intervention, integrated at the appropriate point in the treatment pathway. This included using it as a standalone, and in combination with corticosteroids and orthobiologics, either concurrently or as part of a planned sequence of care.
Other patterns included use after arthroscopy, often around four weeks post-surgery, for joint protection, and earlier use to address synovitis before structural change advances. The unifying idea was proactive joint health: treating the joint environment more deliberately, and managing the first few weeks carefully while the gel integrates, rather than reacting to repeated synovitis flare-ups.

The bottom line

The symposia suggested that, among experienced users, the evidence question for Arthramid is largely settled and the real opportunity now lies in application. The outcomes you see in practice depend less on the product and more on selecting the right joint, confirming the diagnosis, protecting the rehabilitation window, and aligning the people around the horse.

Go deeper. View the Arthramid Clinical Research Journal for the full peer-reviewed evidence base, or speak with the Contura Vet technical services team to discuss case selection and protocols.

Sources: Tnibar et al. 2015 (Acta Veterinaria Scandinavica); de Clifford et al. 2021 (Journal of Equine Veterinary Science, 107:103780); Lowe et al. 2024 (JAVMA, 262:5); Tnibar 2025 (Equine Veterinary Education, 37:161-168); Vallance et al. 2025 (Bain Fallon Lectures).

Typical duration and adverse event figures reflect clinician-reported experience and Arthramid’s adverse-reaction guidance rather than the cited follow-up studies.